Trial: 201907032

A phase 2 study of combination therapy with an IL-15 superagonist (N-803), off-the-shelf CD16-targeted natural killer cells (haNK), and avelumab without cytotoxic chemotherapy in subjects with Merkel cell carcinoma (MCC) that has progressed on or after treatment with a checkpoint inhibitor.



Principal Investigator

Ansstas, George

Disease Site

Melanoma, Skin

Learn more about this study at: